Announcement
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced that it will host an investor conference call on Monday at 8:30 a.m. Eastern Time. U.S. participants can join by dialing +1 833 461 5787, international participants by dialing +1 585 542 9983, and both groups must enter access code 486697901. A live webcast will be available on the Investors section of Mirum’s website, with an archived replay posted thereafter.
Phase 3 EXPAND Study Details
The call will present topline results from the Phase 3 EXPAND study, which evaluates LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients aged six months or older who have ultra‑rare cholestatic liver diseases, including biliary atresia.
Current Approvals and Commercial Portfolio
LIVMARLI is already approved for Alagille syndrome and progressive familial intrahepatic cholestasis. Mirum’s commercial portfolio also comprises ATEBRIOZ for fibrodysplasia ossificans progressiva, CHOLBAM for bile‑acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis.
Clinical‑Stage Pipeline
Beyond LIVMARLI, Mirum’s pipeline includes volixibat, being developed for primary sclerosing cholangitis and primary biliary cholangitis; brelovitug, targeting chronic hepatitis delta virus infection; and MRM‑3379, aimed at treating Fragile X syndrome.
Additional Information
The article was generated with the support of artificial intelligence and reviewed by an editor, as noted in the Reuters disclaimer.